Enzymotec has announced that clinical trials for its lipid-based ingredient line for infant nutrition yielded positive results. These large-scale clinical research trials were conducted on newborn term infants in several institutes globally.
The clinical trial plan is a part of the company's strategy to develop and market its products, which mimic the vital lipids found in mother's milk, such as triglyceride, phospholipids and long-chain polyunsaturated fatty acids (LCPUFA).
Enzymotec Infant Nutrition R&D director Yael Lifshitz said the clinical trials plan represents Enzymotec's ongoing dedication to study the special characteristics of human milk and demonstrate its lipid-based ingredients' health benefits on various infant populations.
"We developed this innovative ingredient and educated the premium infant formula market over the last several years. Enzymotec invested 10% of its revenue in research and development-a percentage considered among the highest in the industry," Lifshitz added.
In the coming months, the company plans to publish four new scientific articles on its lipid-based ingredients for infant nutrition in peer-reviewed journals.
Enzymotec is a research-based biotech company that develops, manufactures and markets innovative lipid-based, bio-functional ingredients and final products. The Enzymotec Infant Nutrition division develops lipid compositions that mimic human milk fat to facilitate healthy infant development.
